Generation of a Specific Immunological Response to FGF-2 Does Not Affect Wound Healing or Reproduction

Immunopharmacology and Immunotoxicology

Volumn 26, Issue 1, 2004, Pages 29-41

  Plum, Stacy M ^a   Vu, Hong A ^a   Mercer, Bobby ^a   Fogler, William E ^a   Fortier, Anne H ^a  

^a ENTREMED INC   (United States)

Author keywords

Angiogenesis; FGF 2; Immunological response; Reproduction; Wound healing

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBODY; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 2 ANTIBODY; HEPARIN; HEPARIN ANTAGONIST; HEPARIN BINDING DOMAIN PEPTIDE VACCINE; HEPARIN DERIVATIVE; LIPOSOME; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FETOTOXICITY; IMMUNE RESPONSE; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; ORGANOGENESIS; PREGNANCY RATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REPRODUCTION; WOUND HEALING;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; ANTIBODY SPECIFICITY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; HEPARIN; HYPERSENSITIVITY, DELAYED; LITTER SIZE; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; PROTEIN BINDING; REPRODUCTION; VACCINATION; WOUND HEALING;

ANIMALIA; MOLVA MOLVA;

EID: 1942487872     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-120029942     Document Type: Article

References (18)

1. Plum, S.M.; Holaday, J.H.; Ruiz, A.; Madsen, J.W.; Fogler, W.E.; Fortier, A.H. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 2001, 19 (9-10), 1294-1303.
2. Abulafia, O.; Sherer, D.M. Angiogenesis in the ovary. Am. J. Obstet. Gynecol. 2000, 182 (1), 240-246.
3. Fujimoto, J.; Sakaguchi, H.; Hirose, R.; Wen, H.; Tamaya, T. Angiogenesis in endometriosis and angiogenic factors. Gynecol. Obstet. Investig. 1999, 48 (1), 14-20.
4. Smith, M.F.; McIntush, E.W.; Smith, G.W. Mechanisms associated with corpus luteum development. J. Anim. Sci. 1994, 72 (7), 1857-1872.
5. Wang, D.I.; Gotlieb, A.I. Fibroblast growth factor 2 enhances early stages of in vitro endothelial repair by microfilament bundle reorganization and cell elongation. Exp. Mol. Pathol. 1999, 66 (3), 179-190.
6. Menetrey, J.; Kasemkijwattana, C.; Day, C.S.; Bosch, P.; Vogt, M.; Fu, F.H.; Moreland, M.S.; Huard, J. Growth factors improve muscle healing in Vivo. J. Bone Jt. Surg., Br. 2000, 82 (1), 131-137.
7. Raballo, R.; Rhee, J.; Lyn-Cook, R.; Leckman, J.F.; Scwartz, M.L.; Vaccarino, F.M. Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J. Neurosci. 2000, 20 (13), 5012-5023.
8. Leconte, I.; Fox, J.C.; Baldwin, H.S.; Buck, C.A.; Swain, J.L. Adenoviral-mediated expression of antisense RNA to fibroblast growth factors disrupt murine vascular development. Dev. Dyn. 1998, 213 (4), 421-430.
9. Ortega, S.; Ittmann, M.; Tsang, S.H.; Ehrlich, M.; Basilico, C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (10), 5672-5677.
10. White, W.I.; Cassatt, D.R.; Madsen, J.; Burke, S.J.; Woods, R.M.; Wassef, N.M.; Alving, C.R. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 1995, 13 (12), 1111-1122.
11. Frey, A.; Mantis, N.; Kozlowski, P.A.; Quayle, A.J.; Bajardi, A.; Perdomo, J.J.; Robey, F.A.; Neutra, M.R. Immunization of mice with peptomers covalently coupled to aluminum oxide particles. Vaccine 1999, 17 (23-24), 3007-3019.
12. Pougatcheva, S.O.; Abernathy, E.S.; Vzorov, A.N.; Compans, R.W.; Frey, T.K. Development of a rubella virus DNA vaccine. Vaccine 1999, 17 (15-16), 2104-2112.
13. Anacker, R.L.; Ribi, E.; Tarmina, D.F.; Fadness, L.; Mann, R.E. Relationship of footpad sensitivity to purified protein derivatives and resistance to airborne infection with Mycobacterium tuberculosis of mice vaccinated with mycobacterial cell walls. J. Bacteriol. 1969, 100 (1), 51-57.
14. Bloch, W.; Huggel, K.; Sasaki, T.; Grose, R.; Bugnon, P.; Addicks, K.; Timpl, R.; Werner, S. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 2000, 14 (15), 2373-2376.
15. Alving, C.R.; Koulchin, V.; Glenn, G.M.; Rao, M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 1995, 145, 5-31.
16. Hoffman, S.L.; Sedegah, M.; Hedstrom, R.C. Protection against malaria by immunization with a Plasmodium yoelii circumsporozite protein nucleic acid vaccine. Vaccine 1994, 12 (16), 1529-1533.
17. Pye, D.; Vandeberg, K.L.; Dyer, S.L.; Irving, D.O.; Goss, N.H.; Woodrow, G.C.; Saul, A.; Alving, C.R.; Richards, R.L.; Ballou, W.R.; Wu, M.J.; Skoff, K. ; Anders, R.F. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine 1997, 15 (9), 1017-1023.
18. Niethammer, A.G.; Xiang, R.; Becker, J.C.; Wodrich, H.; Pert, U.; Karsten, G.; Eliceriri, B.P.; Reisfeld, R.A. DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 2002, 8 (12), 1369-1375.